Name | Title | Contact Details |
---|---|---|
Nancy Tinsley |
Assistant General Counsel | Profile |
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. have entered a global collaboration and licensing agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer and in patients with advanced, unresectable non-small cell lung cancer. Apatorsen is in Phase 2 clinical development and OGX-225 is currently in pre-clinical development.
Applied Reimbursement Techniques is a Mobile, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Harmony Recovery Group is a company that owns and operates multiple drug and alcohol rehab facilities across the Eastern and Midwestern United States. Their facilities specialize in providing compassionate and highly individualized, evidence-based subs...
Apricus Health is designed by Arizona Physicians to improve access to quality care, while lowering costs.
Petvisor is a company that delivers a suite of mobile-enabled technologies to pet care professionals, helping them care for pet families. They provide tools to engage customers, streamline operations, and grow businesses in the veterinary health and pe...